OXB Share Price

Open 3.50 Change Price %
High 4.10 1 Day 0.34 9.80
Low 3.40 1 Week 0.26 7.32
Close 3.81 1 Month 0.26 7.32
Volume 15001065 1 Year -2.30 -37.64
52 Week High 8.45
52 Week Low 2.98
OXB Important Levels
Resistance 2 4.46
Resistance 1 4.19
Pivot 3.77
Support 1 3.43
Support 2 3.16
LON UK Most Active Stocks
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
LLOY 58.15 1.04%
VOD 190.50 -0.47%
VOD 190.50 -0.47%
REX 645.08 0.01%
REX 645.08 0.01%
REX 645.08 0.01%
More..
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
MES 0.28 75.00%
MES 0.28 75.00%
MES 0.28 75.00%
PFLM 5.75 64.29%
BAC 21.70 55.00%
BAC 21.70 55.00%
BAC 21.70 55.00%
GEC 29.21 53.74%
More..
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
BHR 0.02 -33.33%
NBR 0.25 -24.24%
More..

Oxford BioMedica PLC (LON: OXB)

OXB Technical Analysis 2
As on 5th Dec 2016 OXB Share Price closed @ 3.81 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 5.01 & Buy for SHORT-TERM with Stoploss of 3.42 we also expect STOCK to react on Following IMPORTANT LEVELS.
OXB Target for December
1st Target up-side 4.08
2nd Target up-side 4.46
3rd Target up-side 4.83
1st Target down-side 3.02
2nd Target down-side 2.64
3rd Target down-side 2.27
OXB Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.oxfordbiomedica.co.uk
OXB Address
OXB
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001
OXB Latest News
Interactive Technical Analysis Chart Oxford BioMedica PLC ( OXB LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Oxford BioMedica PLC
OXB Business Profile
Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ‘wet’ age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.